![]() |
|
|
Vol. 299, Issue 1, 159-163, October 2001
Division of Gastroenterology, Department of Internal Medicine,
University of Michigan, Ann Arbor, Michigan
Animal studies demonstrate that nizatidine, an H2-receptor
inhibitor, may enhance colonic activity independent of its effect on
acid secretion. The effect of nizatidine on human colonic motility is
unknown. We evaluated the potential prokinetic property of nizatidine
in 12 healthy subjects (10 men and 2 women, age 21-46 years). Each
subject received either nizatidine (600 mg), famotidine (80 mg, a
H2-receptor inhibitor used as a control), or a placebo, on
separate days in randomized order at least 3 days apart. Following an
overnight fast, a three-lumen catheter fitted with a stimulus balloon
and two barostat bags was placed in the descending colon. The
gastrocolonic response was tested by antral balloon inflation and the
colonic peristaltic reflex was evaluated by colonic distension. Changes
in colonic motility were assessed by volume changes in the barostat
bags. Antral distension evoked volume-dependent increases in colonic
motility, maximal at a 300-ml inflation, as demonstrated by a reduced
bag volume. Nizatidine enhanced colonic motility in response to antral
distension at 200 and 300 ml, compared with famotidine and placebo.
Colonic distension evoked volume-dependent increases in colonic
motility proximal to the stimulus balloon. Compared with famotidine and
placebo, nizatidine enhanced the ascending and descending contractile
limbs of the peristaltic reflex but did not affect relaxation distal to
the balloon. In conclusion, nizatidine enhanced the gastrocolonic
response and the colonic peristaltic reflex in healthy subjects.
Further research on the prokinetic action of nizatidine in the colon
may lead to novel treatments for idiopathic constipation.